Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN studyKrish Patel, P. L. Zinzani, Kami J. Maddocks et al.|Blood Advances|2026Cited by 1
A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformationJennifer L. Crombie, Matthew S. Davids, Christine E. Ryan et al.|Blood Advances|2026Cited by 0